Future Oncology, Volume 19, Issue 9 (2023)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Future Oncology, Volume 19, Issue 9 (2023)

See all volumes and issues
Vol 20, 2024 Volume 19, 2023 Vol 18, 2022 Vol 17, 2021 Vol 16, 2020 Vol 15, 2019 Vol 14, 2018 Vol 13, 2017 Vol 12, 2016 Vol 11, 2015 Vol 10, 2014 Vol 9, 2013 Vol 8, 2012 Vol 7, 2011 Vol 6, 2010 Vol 5, 2009 Vol 4, 2008 Vol 3, 2007 Vol 2, 2006 Vol 1, 2005
Download citations Download PDFs Download issue

Editorial

Editorial
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne & Tarek Assi
Pages: 617-620
Published online: 02 May 2023
First Page PreviewforNALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? | Full Text | References | PDF (1.2 MB) | EPUB
  • 94 Views
  • 0 CrossRef citations
  • 0Altmetric

Clinical Trial Protocol

Review Article
Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
Patrick Schöffski, Mehdi Lahmar, Anthony Lucarelli & Robert G Maki
Pages: 621-629
Published online: 29 Mar 2023
AbstractforBrightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
Infographic: A PDF version of this infographic is available as supplemental material.
  • 6684 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Clinical Trial Evaluation

Review Article
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle & Valeria Santini
Pages: 631-642
Published online: 21 Apr 2023
AbstractforSTIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2 | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
Infographic: A PDF version of this infographic is available as supplemental material.
  • 2933 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Short Communication

Brief Report
A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Hook, Marta Vargas Gomes, Ole Hauch & Ash Bullement
Pages: 643-650
Published online: 28 Apr 2023
AbstractforA UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers | Full Text | References | PDF (1.5 MB) | EPUB
  • 890 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Research Article

Article
Tumor-educated platelet SNORA58, SNORA68 and SNORD93 as novel diagnostic biomarkers for esophageal cancer
Qianru Zhang, Zhao Bi, Xingguo Song, Yue Zhang, Shiwen Wang, Li Xie & Xianrang Song
Pages: 651-661
Published online: 02 May 2023
AbstractforTumor-educated platelet SNORA58, SNORA68 and SNORD93 as novel diagnostic biomarkers for esophageal cancer | Full Text | References | PDF (3 MB) | EPUB | Supplemental
  • 80 Views
  • 0 CrossRef citations
  • 0Altmetric

Systematic Review

Review Article
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review
Charlotte L Moss, Teresa Guerrero-Urbano, Ingrid White, Benjamin Taylor, Rebecca Kristeleit, Ana Montes, Louis Fox, Katharina Beyer, Monika Sztankay, Maria M Ratti, Elena S Sisca, Alexandra Derevianko, Steven MacLennan, Nicholas Wood, Lisa M Wintner & Mieke Van Hemelrijck
Pages: 663-678
Published online: 02 May 2023
AbstractforAssessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 173 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
Fabrice Barlesi et al.
Method | Published online: 18 Jul 2024
Open Access
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
Stephen R. D. Johnston et al.
Plain Language Summary of Publication | Published online: 18 Jul 2024
Open Access
TURALIO® Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment
Charles Dharmani et al.
Rapid Communication | Published online: 18 Jul 2024
Open Access
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study
Egbert F. Smit
Plain Language Summary of Publication | Published online: 16 Jul 2024
Open Access
View all latest articles